Bayer Starts Phase III Trials With Radium Dichloride For Prostate Cancer
This article was originally published in PharmAsia News
Bayer Health Care has started an international Phase III trial program with radium 223 dichloride, already approved in Europe and the U.S. as Xofigo (Ra223), for the treatment of metastatic castration-resistant prostate cancer in patients who have not undergone chemotherapy.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.